Healthcare Industry News: S.A.
News Release - April 21, 2011
Misonix Announces New Distribution Agreement for Colombia
FARMINGDALE, N.Y., April 21, 2011 -- (Healthcare Sales & Marketing Network) -- Misonix, Inc. (NaS.A.:MSON ), a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has entered into a new, three year, exclusive distribution agreement with Instrumentacion, S.A. based in Bogota, Colombia. Instrumentacion will sell and distribute the SonaS.A.® Ultrasonic Surgical Aspirator and the BoneS.A.pel™ Ultrasonic Bone Cutter throughout Colombia. The agreement includeS.A.nual minimum purchase requirements.Instrumentacion haS.A. excellent reputation for introducing high tech, S.A.e-of-the-art medical products to the Colombian market and is well known for their commitment to excellence in customer service. Instrumentacion supplieS.A.wide range of specialty medical products to the Colombian market with a focus on head, neck and spine surgery.
The SonaS.A. is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while S.A.ing most vessels. In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaS.A. to safely remove osseous structures, thus providing access to the surgical site.
The BoneS.A.pel iS.A.tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument while minimizing the peril associated with rotary S.A.ps.
"Misonix is pleased to add Instrumentacion to our ever-growing presence in Latin America. Their reputation aS.A.quality distributor of medical equipment and devices in Colombia is well eS.A.lished," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Their success in introducing new medical devices, as well as their commitment to customer service, waS.A.pealing to Misonix. We are particularly pleased that they will be selling two of our key products through their distribution network."
About Misonix:
Misonix, Inc. designs, develops, manufactureS.A.d markets therapeutic ultrasonic medical deviceS.A.d laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical deviceS.A.e used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information iS.A.ailable on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking S.A.ements" that are made purS.A.t to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These S.A.ementS.A.e based on management's current expectationS.A.d are subject to uncertainty and changes in circumS.A.ces. InvestorS.A.e cautioned that forward-looking S.A.ements involve riskS.A.d uncertainties that could cause actual results to differ materially from the S.A.ements made. These factors include general economic conditions, delayS.A.d riskS.A.sociated with the performance of contracts, riskS.A.sociated with international saleS.A.d currency fluctuations, uncertaintieS.A. a result of reS.A.ch and development, acceptable results from clinical studies, including publication of resultS.A.d patient/procedure data with varying levels of S.A.istical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partnerS.A.d implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company'S.A.nual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaimS.A.y obligation to update its forward-looking relationships.
Source: Misonix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!